Polaris today announced that the United States Patent and Trademark Office has issued a notice of allowance for Polaris’ Protein Kinase Inhibitors patent application. This patent is for novel macrocyclic core derived compounds that inhibit protein kinases, including casein kinase 2 (CK2).
CK2 is considered a promising new target in cancer chemotherapy. Inhibition of CK2 activity via small molecules, peptides, anti-sense RNA, and other methods has recently been reported to hinder cell growth of a wide variety of cancer types in vitro and in vivo.
Recent in vitro screening results of PX-228, Polaris’ lead compound, confirm that molecules belonging to this new class of compounds can effectively inhibit the growth of a wide variety of tumor cell lines. The company is currently scaling up PX-228 production in preparation for conducting preclinical animal studies and initiating formulation studies.
Polaris plans to aggressively pursue development of rationally designed small molecule inhibitors of CK2, with particular emphasis focused around their novel patented macrocyclic core structure.
About Polaris Group
Polaris Group is a privately held multinational biopharmaceutical company specializing in the research and development of protein drugs to treat cancer and other debilitating diseases. The company also utilizes a rational structure-based approach for the design of novel small molecule inhibitors of cancer-related protein targets.